Company news
Nuformix PLC news in 2021
Nuformix PLC's news releases, calls and decks from 2021, newest first.
Second Price Monitoring Extn
December 14, 2021
Positive pre-clinical data on NXP002
November 25, 2021
NXP004 patent application filing
November 12, 2021
Price Monitoring Extension
October 4, 2021
Director/PDMR Shareholding - Replacement
September 16, 2021
Licensing agreement with Oxilio for NXP001
September 13, 2021
Letter to shareholders re: Dr Anne Brindley
July 22, 2021
Final results for the year ended 31 March 2021
July 15, 2021
Notice of Allowance of Patent in US
June 7, 2021
Project update - Progress on NXP002 and NXP004
June 1, 2021
Directorate Changes
May 24, 2021
Correction: Holding(s) in Company
April 8, 2021
Result of General Meeting and Total Voting Rights
March 29, 2021
NXP001 (Oncology) - Exercise of Option by Oxilio
March 22, 2021
Initiation of research by Allenby Capital
March 11, 2021
Proposed Placing to raise £1.565 million
March 10, 2021
Research Results
March 2, 2021
Decks in 2021
- Investor Presentation (April 2021)
Investor deck · 23 slides · April 2021